If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly.

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...

While radiotherapy is a highly effective cancer treatment -- useful for about 60 per cent of all cancers -- it may lead to residual cancer that has the potential to hide behind clear scans and lead ...

Sabre has been a great trade. While the S&P 500 was flat, the stock price has climbed by 6.5% to $3.45 per share. This was partly thanks to its solid quarterly results, and the performance may have ...

SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by ...

Sabre's stock performance has been disappointing, with a -59% loss over five years. Check out why I'm neutral on SABR stock.

In this article, we are going to take a look at where Sabre Corporation (NASDAQ:SABR) stands against the other cash-rich ...

Sabre (SABR) announced that SalamAir, Oman’s low-cost carrier, has extended its multi-year partnership with Sabre’s Radixx solutions to support ...

SABRE ($SABR) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$0.08 per share, missing estimates of -$0.07 by $0.01 ...